Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Income towards Parent Company (2016 - 2025)

Sonoma Pharmaceuticals has reported Income towards Parent Company over the past 15 years, most recently at -$819000.0 for Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 11.75% year-over-year to -$819000.0; the TTM value through Dec 2025 reached -$3.4 million, up 10.09%, while the annual FY2025 figure was -$3.5 million, 28.5% up from the prior year.
  • Income towards Parent Company for Q4 2025 was -$819000.0 at Sonoma Pharmaceuticals, down from -$534000.0 in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$534000.0 in Q3 2025 and troughed at -$1.9 million in Q4 2022.
  • A 4-year average of -$1.1 million and a median of -$1.0 million in 2022 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: plummeted 59.86% in 2023 and later skyrocketed 58.89% in 2024.
  • Year by year, Income towards Parent Company stood at -$1.9 million in 2022, then soared by 55.34% to -$866000.0 in 2023, then dropped by 7.16% to -$928000.0 in 2024, then grew by 11.75% to -$819000.0 in 2025.
  • Business Quant data shows Income towards Parent Company for SNOA at -$819000.0 in Q4 2025, -$534000.0 in Q3 2025, and -$1.2 million in Q2 2025.